Abstract Details

Title Stroke Rehabilitation: Factors That Predict Return Home

Topic Neural Repair/Rehabilitation

Presentation(s) P04 - (-)

Poster/Presentation
Number 038

Objective

Background BACKGROUND: In today's health care environment where resources are scarce, discharge planning is an important component of resource allocation. Knowledge of the factors that influence discharge disposition is fundamental to such planning. Further, return to home is an important outcome metric related to the effectiveness of a stroke rehabilitation program.

Design/Methods DESIGN/METHODS: The data set analyzed represents all admissions to the Hamilton Health Sciences Integrated Stroke Program from March 1, 2011 to March 31, 2012. A binary logistic regression analysis was performed to uncover factors predictive of return to home.

Results RESULTS: Of the 268 patients included in the analysis, 67% were discharged home. The most significant predictors of return to home were aggregate admission motor Functional Independence Measure (FIM), aggregate admission cognitive FIM, and pre-stroke living arrangement.

Conclusions CONCLUSIONS: The most significant predictor of return to home (after cognitive and motor FIM scores) was pre-stroke living arrangement; patients who lived with a spouse, partner, or another family member - including extended family - were more likely to return home after stroke rehabilitation. Thus, the availability of a caregiver at home may be a key part of community re-integration for stroke survivors. It may be worthwhile to include these caregivers in the in-patient rehabilitation process, to prepare them for their loved one's return to home. Additionally, more resources should be made available to support caregivers in the community once the patient is discharged home.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Vinjamuri Chari	No disclosure on file
Francesco Muntoni, MD (UCL Institute of Child Health)	Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sarepta. Dr. Muntoni has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Muntoni has received research support from European Commission. The institution of Dr. Muntoni has received research support from Medical Research Council. The institution of Dr. Muntoni has received research support from Biogen. The institution of Dr. Muntoni has received research support from Muscular Dystrophy UK. The institution of Dr. Muntoni has received research support from MDA USA. The institution of Dr. Muntoni has received research support from Sarepta. The institution of Dr. Muntoni has received research support from Association Francoise Myopathies. Dr. Muntoni has received personal compensation in the range of $0-$499 for serving as a Clinical expert with UK NICE Committee.

��ɫ��

��ɫ��